Article Details
Retrieved on: 2022-01-25 17:47:12
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The trial will also include participants aged 30 and above who received two doses of AstraZeneca Plc's (NASDAQ: AZN) AZD1222.
Article found on: www.benzinga.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here